Given the growing prevalence of obesity and overweight observed worldwide, the need for effective and safe pharmacological treatments has become imperative. Five drugs have been authorized for the treatment of obesity, they are indicated for long-term use in patients with BMI> 30 kg / m2, or for those with BMI> 27 kg / m2 who have some associated comorbidity such as DM2, arterial hypertension or dyslipidemia. In general, drugs have two main approaches: modifying the metabolism of macronutrients and acting at the level of the central nervous system (CNS) to modulate the neuroendocrine processes of appetite regulation and satiety.

Currently, glucagon-like peptide-like drugs (GLP-1), which are part of the incretin family, are the main drugs used in the medical arsenal since they allow a weight reduction> 5% in the first year of treatment.

Treatment should be individualized based on comorbidities, drug tolerance, cost, and availability, among other factors.